Vaccination
Science
Microscope
Pneumococcal Vaccine Candidate MVX01

A pneumolysin protein fused with Choline binding protein A epitopes creates our serotype-independent, dual-antigen vaccine to combat pneumococcal disease

C. difficile Vaccine Candidate MVX02

C. difficile infections result in 14,000 deaths per year in the United States.  Matrivax is targeting both  the pathogen and the toxoids in our unique vaccine.

Applying breakthrough science to develop innovative, clinically-impactful vaccines for people in need around the world

STREPTOCOCCUS
PNEUMONIAE
14.5 MM
annual serious cases worldwide
1.6 MM
annual deaths worldwide
$8 billion
projected global market

1

2

CLOSTRIDIODES
DIFFICILE
~225,000
annual cases in the USA
14,000
deaths in the USA alone
>$1 billion
projected global market

3

3

1. WHO, 2000;   2. WHO, 2005;   3. CDC, 2019

Contact Us

650 Albany Street, Suite 117, Boston, MA 02118 

inquiry@matrivax.com  |  Tel: 617-358-7640

Success! Message received.